IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1249.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 15-Sep-2016
Cell
New strategy identified for treating acute myeloid leukemia
A multi-institutional academic and industry research team led by investigators from Massachusetts General Hospital and the Harvard Stem Cell Institute has identified a promising new approach to the treatment of acute myeloid leukemia
Harvard Stem Cell Institute, Amelia Peabody Foundation, National Institutes of Health, American Society of Hematology, Leukemia and Lymphoma Society, Alex's Lemonade Stand Foundation, Harvard Catalyst, American Cancer Society

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 14-Sep-2016
Environmental Science & Technology
Potentially harmful chemicals widespread in household dust
Household dust exposes people to a wide range of toxic chemicals from everyday products, according to a study led by researchers at Milken Institute School of Public Health (Milken Institute SPH) at the George Washington University. The multi-institutional team conducted a first-of-a-kind meta-analysis, compiling data from dust samples collected from homes throughout the United States to identify the top 10 toxic chemicals found in dust.
Natural Resources Defense Council, NIH/National Institute of Environmental Health Sciences,US Department of Housing and Urban Development

Contact: Kathy Fackelmann
kfackelmann@gwu.edu
202-994-8354
George Washington University Milken Institute School of Public Health

Public Release: 14-Sep-2016
Cancer Discovery
Discovery offers prospect of shorter treatment and cure for chronic myelogenous leukemia
Although targeted drugs like Gleevec have revolutionized the treatment of chronic myelogenous leukemia, patients generally must take them for the rest of their lives and may cease benefiting from them over time. In new research that could suggest a road to cure, scientists have found that CML stem cells die in response to inhibition of a protein called Ezh2. Drugs that target the protein are currently being tested in clinical trials for other cancers.
National Insitutes of Health, Hyundai Hope on Wheels

Contact: Irene Sege
irene.sege@childrens.harvard.edu
617-919-3110
Dana-Farber Cancer Institute

Public Release: 13-Sep-2016
Cell Reports
Anti-tumor immunity identified with new ovarian cancer treatment strategy
New research from The Wistar Institute demonstrates how a drug already in clinical trials could be used to boost anti-tumor immunity and cause T-cells to target the cancer directly while minimizing side effects.
NIH/National Cancer Institute, US Department of Defense, Ovarian Cancer Research Fund, The Jayne Koskinas & Ted Giovanis Breast Cancer Research Consortium at Wistar

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 13-Sep-2016
JAMA
Study examines survival outcomes after different lung cancer staging methods
In a study appearing in the Sept. 13 issue of JAMA, Jouke T. Annema, M.D., Ph.D., of the Academic Medical Center, Amsterdam, and colleagues examined five-year survival after endosonography vs mediastinoscopy for mediastinal nodal staging of lung cancer.

Contact: Jouke T. Annema, M.D., Ph.D.
j.t.annema@amc.uva.nl
The JAMA Network Journals

Public Release: 12-Sep-2016
Nature Immunology
Study explains mechanisms behind glioblastoma influence on the immune system
Glioblastomas exert an influence on the microglia, immune cells of the brain, which causes them to stimulate cancer growth rather than attacking it. In a study published in the journal Nature Immunology, an international research team led from Sweden's Karolinska Institutet now explains the molecular mechanisms behind this action.
Swedish Research Council, Swedish Childhood Cancer Foundation, Swedish Cancer Society, Swedish Brain Fund, and others

Contact: KI Press Office
pressinfo@ki.se
46-852-486-077
Karolinska Institutet

Public Release: 9-Sep-2016
2016 Palliative Care in Oncology Symposium
JAMA Oncology
Voices of patients and oncologists must be heard, study says
Specifically training oncologists and their patients to have high-quality discussions improves communication, but troubling gaps still exist between the two groups, according to a new study in JAMA Oncology.
NIH/National Cancer Institute, National Institutes of Health

Contact: Leslie Orr
leslie_orr@urmc.rochester.edu
University of Rochester Medical Center

Public Release: 8-Sep-2016
JAMA Otolaryngology - Head & Neck Surgery
Chronic Sinusitis Associated With Certain Rare Head and Neck Cancers among Elderly, Although AbsoluChronic sinusitis associated with certain rare head and neck cancers among elderly, although absolut
In a study published online by JAMA Otolaryngology-Head & Neck Surgery, Daniel C. Beachler, Ph.D., M.H.S., and Eric A. Engels, M.D., M.P.H., of the National Cancer Institute, Bethesda, Md., evaluated the associations of chronic sinusitis with subsequent head and neck cancer in an elderly population.

Contact: NCI Press Office
ncipressofficers@mail.nih.gov
The JAMA Network Journals

Public Release: 8-Sep-2016
Journal of National Cancer Institute
Tamoxifen resistance linked to high estrogen levels in utero
An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals. The study provides a new path forward in human research as about half of the breast cancers treated with this common cancer therapy do not respond well, say researchers at the Georgetown Lombardi Comprehensive Cancer Center, who led the multi-institutional research.
National Institutes of Health, Department of Defense

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 8-Sep-2016
JCI Insight
Cancer cells metastasize by hitching a ride on platelets
In this issue of JCI Insight, Pierre Henri Mangin and colleagues at the Etablissement Français du Sang-Alsace have shown that a molecule expressed on platelets, known as α6β1 integrin, participates in tumor metastasis by promoting interactions between tumor cells and platelets.
INSERM, Etablissement Français du Sang, Association de Recherche et Développement en Médecine et Santé Publique, and Institut National du Cancer

Contact: Corinne Williams
press_releases@the-jci.org
JCI Journals

Public Release: 8-Sep-2016
JAMA Oncology
After long-term follow-up, study looks at prognostic factors for breast cancer
A new study published online by JAMA Oncology is long-term analysis of prognostic factors among some patients with breast cancer who were treated with breast-conserving therapy in the EORTC 'boost no boost' trial, which evaluated the influence of a 'boost' dose in radiotherapy.

Contact: Conny Vrieling, M.D., Ph.D.
conny.vrieling@grangettes.ch
The JAMA Network Journals

Public Release: 8-Sep-2016
Oncotarget
Study shows how Chinese medicine kills cancer cells
Researchers at the University of Adelaide have shown how a complex mix of plant compounds derived from ancient clinical practice in China -- a Traditional Chinese Medicine -- works to kill cancer cells.

Contact: David Adelson
david.adelson@adelaide.edu.au
61-045-980-7714
University of Adelaide

Public Release: 8-Sep-2016
Cell
New insights into tumor-infiltrating T cells
Investigators from Brigham and Women's Hospital have identified a distinct gene module for T cell dysfunction distinct from activation in tumor-infiltrating T cells, thus paving the way for the development of new precision therapeutics.
National Institutes of Health, American Cancer Society Klarman Cell Observatory at the Broad, Institute, Howard Hughes Medical Institute

Contact: Haley Bridger
hbridger@partners.org
617-525-6383
Brigham and Women's Hospital

Public Release: 8-Sep-2016
Three in 4 don't know obesity causes cancer
Three out of four (75 percent) people in the UK are unaware of the link between obesity and cancer, according to a new Cancer Research UK report published today.

Contact: Stephanie McClellan
stephanie.mcclellan@cancer.org.uk
020-346-98300
Cancer Research UK

Public Release: 7-Sep-2016
Scientific Reports
Computerized tissue image analysis reveals underlying genomics of ER+ breast cancer
The number of tubules in tumors may predict which women with estrogen receptor positive (ER+) breast cancer will benefit from hormone therapy alone and which require chemotherapy. A computer program to automatically count the tubules correlated with the scores produced by the current best test differentiating between indolent and aggressive ER+ cancers.
NIH/National Cancer Institute, NIH/National Institute of Diabetes and Digestive and Kidney Diseases, DOD/Prostate Cancer Synergistic Idea Development Award, DOD/Lung Cancer Idea Development New Investigator Award, and others

Contact: Kevin Mayhood
kevin.mayhood@case.edu
216-534-7183
Case Western Reserve University

Public Release: 7-Sep-2016
Angewandte Chemie
Sugar transforms a traditional Chinese medicine into a cruise missile
A chemical biologist and his colleagues at the Johns Hopkins University School of Medicine report that tests of triptolide in human cells and mice are vastly improved by the chemical attachment of glucose to the triptolide molecule.
NIH/National Center for Advancing Translational Sciences

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 7-Sep-2016
British Journal of Sports Medicine
Physical activity may offset some of alcohol's lethal harms
An international research collaboration, led by University of Sydney, has found that exercising at even basic recommended weekly physical activity levels (at least 150 minutes of moderate-intensity activity) may offset some of the harmful effects of drinking alcohol. Published today in the British Journal of Sports Medicine, this first-of-its-kind study found that for alcohol drinkers, physical activity may decrease the risks of dying both from cancer and from 'all-cause mortality' that is, deaths from any cause.

Contact: Kobi Print
kobi.print@sydney.edu.au
61-481-012-729
University of Sydney

Public Release: 7-Sep-2016
Journal of Agricultural and Food Chemistry
Ginger and chili peppers could work together to lower cancer risk
For many people, there's nothing more satisfying than a hot, spicy meal. But some research has suggested that capsaicin, the compound that gives chili peppers their kick, might cause cancer. Now researchers show in mouse studies that the pungent compound in ginger, 6-ginergol, could counteract capsaicin's potentially harmful effects. In combination with the capsaicin, 6-gingerol could lower the risk of cancer, they say. The study appears in ACS' Journal of Agricultural and Food Chemistry.

Contact: Michael Bernstein
m_bernstein@acs.org
202-872-6042
American Chemical Society

Public Release: 7-Sep-2016
Physics Review Letters
A new way of taming ions can improve future health care
A group of researchers at Chalmers University of Technology has discovered a completely new way of using lasers to accelerate ion beams. In time, the new technique could possibly give more people access to advanced cancer treatment. The results were recently published in the high impact journal Physical Review Letters.
Knut and Alice Wallenberg Foundation

Contact: Johanna Wilde
johanna.wilde@chalmers.se
46-317-722-029
Chalmers University of Technology

Public Release: 7-Sep-2016
EBioMedicine
Experimental drug could stop melanoma, other cancers, research suggests
An experimental cancer drug works differently than intended and shows significant promise for stopping melanoma and possibly other forms of cancer.
NIH/National Cancer Institute

Contact: Josh Barney
jdb9a@virginia.edu
434-906-8864
University of Virginia Health System

Public Release: 7-Sep-2016
Science Translational Medicine
Patients with advanced lymphoma in remission after T-cell therapy
In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made from a patient's own immune cells that are then genetically engineered to better identify and kill cancer cells.
Juno Therapeutics Inc., National Institutes of Health, Washington state's Life Science Discovery Fund, Bezos Family Foundation

Contact: Claire Hudson
media@fredhutch.org
206-667-2210
Fred Hutchinson Cancer Research Center

Public Release: 7-Sep-2016
10 Cancer Moonshot Blue Ribbon Panel recommendations embraced by NCI
When 28 distinguished individuals convened earlier this year to help shape the scientific mission at the National Cancer Institute (NCI) of Vice President Joe Biden's National Cancer Moonshot Initiative, they were given five months to draft guidelines to accelerate cancer research, prevention and care. On Wednesday, the National Cancer Advisory Board approved the Blue Ribbon Panel's 10 recommendations.

Contact: Yadira Galindo
ygalindo@ucsd.edu
858-249-0456
University of California - San Diego

Public Release: 7-Sep-2016
EBioMedicine
Researchers find molecular link behind aspirin's protective powers
Researchers at Duke Health have identified a new mechanism of aspirin's action that appears to explain the drug's diverse benefits.
National Institutes of Health

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center

Public Release: 7-Sep-2016
PLOS Biology
Fruit flies yield clues on cancerous tumor hotspots
A Florida State University research team, in coordination with a team from Japan, has found that the epithelial tissues that line the surfaces of organs throughout the body intrinsically have hot spots for cancerous tumors. They discovered this by examining a common household pest -- the fruit fly.

Contact: Kathleen Haughney
khaughney@fsu.edu
850-644-1489
Florida State University

Public Release: 7-Sep-2016
Molecular Endocrinology
Scientists identify genes that disrupt response to breast cancer treatment
In breakthrough research on breast cancer, a team at the University of Illinois discovered that higher levels of the nuclear transport gene XPO1 indicate when a patient is likely to be resistant to the popular drug tamoxifen. The team is led by food science and human nutrition professor Zeynep Madak-Erdogan.

Contact: Sharita Forrest
slforres@illinois.edu
217-244-1072
University of Illinois at Urbana-Champaign

Showing releases 1-25 out of 1249.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases

     

 

EurekAlert!